Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study

Puntos clave

• Improved survival rates were observed with immune checkpoint inhibitor rechallenge in nasopharyngeal carcinoma patients.
• The prognostic model accurately stratified patients, predicting outcomes based on their response to previous treatments.
• Real-world data collection provided insights into the effectiveness of immune checkpoint inhibitors in recurrent disease.
• Findings suggest that rechallenging patients may enhance overall treatment strategies for aggressive nasopharyngeal carcinoma.